• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORDIS CORPORATION TRAPEASE FILTER; THROMBECTOMY SYSTEMS (DQO)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORDIS CORPORATION TRAPEASE FILTER; THROMBECTOMY SYSTEMS (DQO) Back to Search Results
Catalog Number 466P306X
Device Problem Occlusion Within Device (1423)
Patient Problem Thrombosis (2100)
Event Date 10/01/2015
Event Type  Injury  
Manufacturer Narrative
Complaint conclusion: as reported in the publication by nagarsheth, et al catheter-directed therapy is safe and effective for the management of acute inferior vena cava thrombosis; annals of vascular surgery (2015); 1373-1379; all 12 patients who had a trapease filter experienced acute ivc (inferior vena cava) filter thrombosis.All patients were treated under conscious sedation and local anesthesia.Imaging of the access site was performed at the start of the procedure by dus imaging, and access was obtained via the common femoral, popliteal, or internal jugular vein by ultrasound-guided puncture depending on physician preference.Occluded ivc filters were traversed using a.035-in guide-wire.When a severely occluded ivc filter had extension of thrombus into both common iliac veins, bilateral wire access was obtained to perform dual-catheter pmt/cdt.This provided a more substantial flow lumen within the ivc and iliac veins.Pmt (angiojet/trellis) was performed within the occluded filter based on thrombus burden and symptomatology.After the intervention, all patients were continued on medical therapy consisting of therapeutic anticoagulation with heparin (18 u/kg) or enoxaparin sodium (1 mg/kg every 12 hr) followed by oral anticoagulation therapy for a period of 6 months.Patients who had a prior episode of vte were kept on lifelong anticoagulation.The products were not returned for analysis.A review of the manufacturing records could not be conducted without a lot number.The purpose of a vena cava filter is to catch thrombus from the lower extremities as it travels along normal blood flow patterns up towards the heart.Thrombus in the filter does not represent a device malfunction.Thrombosis in the filter is a well-known potential complication and occurs in approximately 3.6 to 11.2 % of all patients¿.Factors that may have influenced the event include patient, pharmacological and lesion.Thrombosis in the filter is a well-known potential complication and occurs in approximately 3.6 to 11.2 % of all patients.Factors that may have influenced the events include patient, pharmacological and lesion.There is no medical evidence of a causal relationship between the vena cava filter and the formation the thromboses.Without a lot number to conduct a dhr review, it is not possible to determine if the reported failure could be related to the manufacturing process.Therefore no corrective and preventive actions will be taken at this time.Please note the attached literature article.Literature citation: nagarsheth et al.(2015).Catheter-directed therapy is safe and effective for the management of acute inferior vena cava thrombosis.Annals of vascular surgery, 1373-1379.Please note that this mdr report is being submitted for multiple patients with no specific product information or patient information available.Concomitant products: heparin (18 u/kg) or enoxaparin sodium (1 mg/kg every 12 hr), infusion therapy (18 u/kg), followed by oral anticoagulation therapy for a period of 6 months.Patients who had a prior episode of vte were kept on lifelong anticoagulation.0.035-in unk guide wire.This mdr is related to mdr report#¿s: 9616099-2015-00596, 9616099-2015-00595, 9616099-2015-00594, 9616099-2015-00593, 9616099-2015-00592, 9616099-2015-00591, 9616099-2015-00590, 9616099-2015-00597, 9616099-2015-00589, 9616099-2015-00587, 9616099-2015-00586, 9616099-2015-00585.
 
Event Description
As reported in the publication by nagarsheth, et al catheter-directed therapy is safe and effective for the management of acute inferior vena cava thrombosis; annals of vascular surgery (2015); 1373-1379; all 12 patients who had a trapease filter experienced acute ivc (inferior vena cava) filter thrombosis.All patients were treated under conscious sedation and local anesthesia.Imaging of the access site was performed at the start of the procedure by dus imaging, and access was obtained via the common femoral, popliteal, or internal jugular vein by ultrasound-guided puncture depending on physician preference.Occluded ivc filters were traversed using a.035-in guide-wire.When a severely occluded ivc filter had extension of thrombus into both common iliac veins, bilateral wire access was obtained to perform dual-catheter pmt/cdt.This provided a more substantial flow lumen within the ivc and iliac veins.Pmt (angiojet/trellis) was performed within the occluded filter based on thrombus burden and symptomatology.After the intervention, all patients were continued on medical therapy consisting of therapeutic anticoagulation with heparin (18 u/kg) or enoxaparin sodium (1 mg/kg every 12 hr) followed by oral anticoagulation therapy for a period of 6 months.Patients who had a prior episode of vte were kept on lifelong anticoagulation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRAPEASE FILTER
Type of Device
THROMBECTOMY SYSTEMS (DQO)
Manufacturer (Section D)
CORDIS CORPORATION
14201 nw 60th avenue
miami lakes FL
Manufacturer Contact
cecil navajas
circuito interior norte #1820
juarez chihuahua 32580
MX   32580
7863133880
MDR Report Key5242706
MDR Text Key31827519
Report Number9616099-2015-00592
Device Sequence Number1
Product Code DQO
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K020316
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Health Professional
Type of Report Initial
Report Date 11/12/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number466P306X
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 11/12/2015
Initial Date FDA Received11/23/2015
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-